MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Read full paper →- Authors
- Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah E. Kleiman, Kelly Parker-Guilbert, Marcela Ot’alora G., Wael Garas, Casey Paleos, Ingmar Gorman, Christopher R. Nicholas, Michael C. Mithoefer, Shannon Carlin, Bruce Poulter, Ann T. Mithoefer, Sylvestre Quevedo, G. Beverly Wells, Sukhpreet Klaire, Bessel van der Kolk, Keren Tzarfaty, Revital Amiaz, Ray Worthy, Scott Shannon, Joshua Woolley, Cole J. Marta, Yevgeniy Gelfand, Emma Hapke, Simon Amar, Yair Wallach, Randall Brown, Scott Hamilton, Julie B. Wang, Allison R. Coker, Rebecca Matthews, Alberdina de Boer, Berra Yazar‐Klosinski, Amy Emerson, Rick Doblin
- Journal
- Nature Medicine
- Year
- 2021
- Citations
- 932
TL;DR
MDMA-assisted therapy, when combined with a structured therapeutic protocol, led to a significantly greater reduction in severe PTSD symptoms and functional impairment compared to therapy with an inactive placebo, with 67% of participants in the MDMA group no longer meeting PTSD diagnostic criteria after treatment.
What they tested
This study investigated the effectiveness and safety of